? SmartAnalyst | Consulting , Research, Analytics | Smart Analyst

SMARTOncology Tumor Insights provides data-driven insights into the future market dynamics for over 25 tumors.

With a forward-looking focus on the clinical landscape, SMARTOncology Tumor Insights is the best way to understand your market opportunity, access detailed clinical data, and receive updates on the changing landscape.

Oncology is the cornerstone of SmartAnalysts consulting business, and we have developed the series as a foundation for our clients' key clinical and commercial development and BD&L decisions.

Have confidence that you understand the implications of the changing landscape and immuno-oncology activities, and that you know what's required to inform clinical investment decisions.

With the SMARTOncology Tumor Insights, you will:

  • Obtain a forward-looking perspective and expert views* on key tumors, in order to shape commercial and clinical decisions for pipeline assets and BD opportunities
  • Understand how the competitive dynamics would impact the treatment paradigm in the coming 3-5 years
  • Acquire comprehensive foundational data with rich clinical data and insights
  • Keep track of the immunotherapy landscape, including outcomes that may impact strategic decisions on an IO/ non-IO in the portfolio
  • Stay current, with updates delivered twice each year
  • Get a global perspective, with insights on the US, EU and select Asia-Pacific markets
  • Consolidate key insights and data in one concise report - and avoid internal "fire drills" accessing data
  • Quickly get up to speed on a tumor when evaluating a BD&L opportunity
  • Easily cut-and-paste data and slides into your own presentations

Table of Contents

Executive Summary

Disease Overview

  • Anatomy/Histology
  • Symptoms/Diagnosis
  • Staging/Classification

Epidemiology
  • Treatment starts by line of therapy for 2016 - 2025*
Current Treatment Landscape

  • Treatment Algorithm
  • Benchmarks
  • Timelines: Approvals and Patent Expirations
  • Unmet Needs

Emerging Treatment Landscape

  • Clinical Pipeline Activity
  • Summary of IO Activity
  • Summary of Key Emerging Agents
  • Emerging Patient Segments

Current and Emerging Biomarkers
Pricing, Reimbursement and Cost-effectiveness Analysis
Clinical Development Pathway in Key Disease Opportunities
Appendix

  • Trial Profiles of Key Emerging Agents
  • Trial Failures

2017 Planner

Available Now

Solid Tumors


Esophageal Cancer
NSCLC
Gastric Cancer
SCLC
Pancreatic
Mesothelioma
HCC
TNBC
Colorectal
HER2+ Breast Cancer
RCC
HER2 Neg HR+ Breast Cancer*
Bladder Cancer
Ovarian Cancer
Prostate
Melanoma
 
SCCHN

Hematologic Malignancies


AML
Myelofibrosis*
iNHL
MDS
aNHL
Multiple Myeloma
CLL
CML
Updates available following
ASH 2016, ASCO GI/GU Cancers (Jan, Feb, April 2017)     
AACR/ASCO/EHA (May, June, Aug 2017)

Additional tumors can be covered or we can customize reports, as required


Our Practice lead Anshu Mittal Roy, PhD, would be happy to take you through the SMARTOncology Tumor Insights, and discuss how the reports and our consulting services can help inform key decision points for your pipeline and business. Please contact Trish Kane at tkane@smartanalyst.com to schedule a brief web conference.